Safety, simplicity and convenience of a modified prefilled insulin pen

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 13, 2008, Pages 2223-2232

  Sommavilla, B ^a   Jorgensen C ^b   Jensen, K H ^b  

^a Diabetes Education Center   (Austria)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Aspart pen; Detemir pen; FlexPen; Insulin device; Next Generation FlexPen; Patient preference

Indexed keywords

INSULIN ASPART; INSULIN DETEMIR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG LABELING; DRUG PACKAGING; DRUG PREFERENCE; DRUG SAFETY; FEMALE; HEALTH SURVEY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NEEDLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ATTITUDE; PREFILLED INSULIN PEN; QUESTIONNAIRE; SELF INJECTION; TRUST;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS; DISPOSABLE EQUIPMENT; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; MIDDLE AGED; PATIENT SATISFACTION; QUESTIONNAIRES;

EID: 52049127009     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.13.2223     Document Type: Article

References (26)

1. Korytkowski M, Bell D, Jacobsen C, Suwannasari R. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 2003;25(11):2836-48
2. Korytkowski M, Niskanen L, Asakura T. FlexPen: addressing issues of confidence and convenience in insulin delivery. Clin Ther 2005;27(Suppl B):S89-100
3. Bohannon NJ, Channesian JP, Burdan AL, et al. Patient and physician satisfaction with the Humulin/Humalog Pen, a new 3.0-mL prefilled pen device for insulin delivery. Clin Ther 2000;22(9):1049-67
4. Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther 2004;26(9):1498-505
5. Lombardo F, Salzano G, Messina MF, De Luca F. Compliance and administration methods in management of type 1 diabetes. Acta Biomed 2005;76(Suppl 3):66-9
6. IMS Health. Estimated number of patients using FlexPen®, based on worldwide sales in number of packs sold, IMS world wide data Q4'07 and Daily Defined Dosage (DDD) for insulin as issued by WHO. 2007
7. Asakura T, Seino H. Insulin dosing accuracy with FlexPen® versus syringe by healthcare professionals and healthy volunteers. Diabetes 2005;54(Suppl 1).A498-9
8. Asakura T, Seino H, Kageyama M, Yohkoh N. Dosing accuracy of two insulin pre-filled pens. Curr Med Res Opinion 2008;24(5):1429-34
9. Hänel H, Weise A, Sun W, et al. Differences in the dose accuracy of insulin pens. J Diabetes Sci Tech 2008;2(3):478-81
10. Asakura T. Comparison of the dosing accuracy of two insulin injection devices. J Clin Res 2005;8:33-40
11. Pfutzner A, Reimer T, Frokjaer LPF, Jorgensen C. Prefilled insulin device with reduced injection force: patient perception and accuracy. Curr Med Res Opin 2008; 24(9):2545-9. Published online on 29 July 2008; doi:10.1185/03007990802329264
12. Rubin RR, Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/ soluble aspart) versus alternative treatment strategies. Diabetes Care 2004;27(10):2495-7
13. Niskanen L, Jensen LE, Rastam J, et al. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin Ther 2004;26(4):531-40
14. Asakura T, Seino H. A comparison of the usability of two types of disposable pen (FlexPen versus Humalog Kit) containing rapid-acting insulin analogues. Diabetes Metab 2003;29:S236
15. Dreyer M. Comparison of metabolic control, safety, handling and patient acceptance of FlexPen with NovoLet in type 1 and type 2 diabetes patients. J Clin Res 2005;8:1-7
16. Savas S, Koroglu BK, Koyuncuoglu HR, et al. The effects of the diabetes related soft tissue hand lesions and the reduced hand strength on functional disability of hand in type 2 diabetic patients. Diabetes Res Clin Pract 2007;77(1):77-83
17. Schady W, Abuaisha B, Boulton AJ. Observations on severe ulnar neuropathy in diabetes. J Diabetes Complications 1998;12(3):128-32
18. Ziegler D, Gries FA, Spuler M, Lessmann F. The epidemiology of diabetic neuropathy. DiaCAN Multicenter Study Group. Diabet Med 1993;10(Suppl 2):S82-6
19. Clarke A, Spollett G. Dose accuracy and injection force dynamics of a novel disposable insulin pen. Expert Opin Drug Deliv 2007;4(2):165-74
20. Rissler J, Jorgensen C, Rye Hansen M, Hansen N-A. Evaluation of injection force dynamics of a modified prefilled insulin pen. Expert Opin Pharmacother 2008;9(13):2217-22
21. Phillips W, Lando H. Insulin confusion: an observation. Diabetes Care 2002;25(6):1103-4
22. Adletsberg MA, Fernando S, Spollett GR, Inzucchi SE. Glargine and lispro: two cases of mistaken identity. Diabetes Care 2002;25(2):404-5
23. Haak T, Edelman S, Walter C, et al. Comparison of usability and patient preference for the new disposable insulin device Solostar versus Flexpen, lilly disposable pen, and a prototype pen: an open-label study. Clin Ther 2007;29(4):650-60
24. Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of hird-party managed care claims data [Discussion 0-1]. Clin Ther 2006;28(10):1712-25
25. Pawaskar MD, Camacho FT, Anderson RT, et al. Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther 2007;29 Spec No:1294-305
26. Asakura T, Seino H. Handling and safety of two insulin injection pens (FlexPen® and OptiClik®) in insulin-naive type 2 diabetes patients. Diabetes 2006;55(Suppl 1):A457